Biometry
Developer of an at‑home respiratory monitoring platform that combines breath biomarker measurement (FeNO), a mobile app, and data science to predict and prevent asthma and COPD exacerbations. The company is developing a portable FeNO test integrated with disposable strips and predictive models; products are in development and not yet cleared by the FDA.
Industries
Nr. of Employees
small (1-50)
Patents
Mini point of care gas chromatographic test strip and method to measure analytes
US-12117429-B2
View DetailsMethods of and systems for measuring analytes using batch calibratable test strips
US-12038428-B2
View DetailsMethods of and systems for measuring analytes using batch calibratable test strips
US-11255840-B2
View DetailsMini point of care gas chromatographic test strip and method to measure analytes
US-11175268-B2
View Details
Mini point of care gas chromatographic test strip and method to measure analytes
US-12117429-B2
View DetailsMethods of and systems for measuring analytes using batch calibratable test strips
US-12038428-B2
View DetailsMethods of and systems for measuring analytes using batch calibratable test strips
US-11255840-B2
View DetailsMini point of care gas chromatographic test strip and method to measure analytes
US-11175268-B2
View DetailsProducts
At‑home portable FeNO breath test with companion mobile app (product under development)
Portable, non‑invasive breath testing system measuring FeNO using a sensor and disposable strips, paired with a mobile application and analytics for monitoring and risk prediction.
fenoTRACK
A portable, non-invasive breath test device that measures type 2 airway inflammation via fractional exhaled nitric oxide (FeNO) to help identify patients at risk of asthma and COPD exacerbations and enable early detection of exacerbations.
At‑home portable FeNO breath test with companion mobile app (product under development)
Portable, non‑invasive breath testing system measuring FeNO using a sensor and disposable strips, paired with a mobile application and analytics for monitoring and risk prediction.
fenoTRACK
A portable, non-invasive breath test device that measures type 2 airway inflammation via fractional exhaled nitric oxide (FeNO) to help identify patients at risk of asthma and COPD exacerbations and enable early detection of exacerbations.
Services
Mobile app programs delivering guideline‑based education and coaching to support asthma/COPD self‑management and reduce exacerbation risk.
Mobile app programs delivering guideline‑based education and coaching to support asthma/COPD self‑management and reduce exacerbation risk.
Expertise Areas
- Asthma and COPD diagnostics
- Breath biomarker measurement (FeNO)
- Digital health and remote patient monitoring
- Predictive risk modeling and validation
Key Technologies
- Fractional exhaled nitric oxide (FeNO) measurement
- Disposable test‑strip breath assays
- Electrochemical biosensors
- Nanomaterials and sensor coatings
News & Updates
Announcement of an oversubscribed $5 million Seed funding round to advance development of a portable FeNO monitoring solution for asthma and COPD; company preparing for regulatory submission.
Raised $5 million in an oversubscribed Seed round to advance development of the FeNO monitoring solution.
Announcement of an oversubscribed $5 million Seed funding round to advance development of a portable FeNO monitoring solution for asthma and COPD; company preparing for regulatory submission.
Raised $5 million in an oversubscribed Seed round to advance development of the FeNO monitoring solution.